Urinary excretion (0–24 h) of debrisoquine, 4-hydroxydebrisoquine, and 3,4-dehydrodebrisoquine in 13 human volunteers genotyped for CYP2D6
Debrisoquine (10 mg) was administered by mouth as debrisoquine hemisulfate (12.8 mg). Results are expressed as percentage of dose excreted.
Subject No. (Genotype) | Debrisoquine | 4-Hydroxy-debrisoquine | 3,4-Dehydro-debrisoquine |
|---|---|---|---|
| 1 (*1/*1) | 18.6 | 30.4 | 5.1 |
| 2 (*1/*1) | 7.8 | 33.6 | 12.7 |
| 3 (*1/*1) | 16.8 | 17.5 | 3.1 |
| 4 (*1/*1) | 8.9 | 21.1 | 10.1 |
| 5 (*1/*1) | 7.0 | 46.5 | 6.1 |
| 6 (*1/*1) | 9.7 | 37.3 | 27.6 |
| 7 (*1/*1) | 9.6 | 28.0 | 3.1 |
| 8 (*1/*1) | 12.6 | 24.1 | 15.6 |
| 9 (*1/*1) | 17.1 | 14.4 | 9.0 |
| Mean ± S.E.M. | 12.0 ± 1.5 | 28.1 ± 3.4 | 10.3 ± 2.6 |
| 10 (*4/*4) | 73.0 | 1.4 | 2.1 |
| 11 (*4/*4) | 43.4 | <0.35 | 0 |
| 12 (*4/*4) | 43.5 | <0.31 | 1.4 |
| 13 (*4/*4) | 53.2 | <0.7 | 0.6 |
| Mean ± S.E.M. | 53.3 ± 7.0 | 0.7 ± 0.3 | 1.0 ± 0.5 |
|
Significance (P) (Mann-Whitney U test)
|
0.0014
|
0.0014
|
0.0014
|